300 million people around the world live with a rare disease. This perhaps explains the seemingly endless growth of orphan drugs and the forecasted $300bn market by 2028.
Is this growth set to continue? Well, in the short term, yes. Longer term? Perhaps not. However, between now and 2028, Evaluate Pharma forecasts growth of close to 12% compared to around 7% for the wider market, so there is still much to consider.
In our latest focused report on orphan drugs we dig into the companies, drugs and therapy areas that are fuelling this growth, and look at what’s in the pipeline for the coming years.
Download the full report now.
